Novo Nordisk, a leading leading global healthcare company, recently announced the acquisition of Inversago Pharma, a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.
Inversago presented at the OBIO® Investment Summit.